28 Papers
207 Citations
H. Groen is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 10, co-authored 26 publications.
Chat about Author
Papers
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
Fabrice Barlesi,Arnaud Scherpereel,Vera Gorbunova,Radj Gervais,Anders Vikström,Christos Chouaid,Antonio Chella,Jeong-Ho Kim,Myung-Ju Ahn,Martin Reck,Antonio Pazzola,H. T. Kim,Joachim G.J.V. Aerts,Claire Morando,Anderson Loundou,H. Groen,Achim Rittmeyer +16 more
TL;DR: In an unselected population of nsNSCLC patients achieving disease control on platinum-based induction therapy, maintenance with bevacizumab-pemetrexed was associated with a nonsignificant increase in OS over bevacsumab alone.
172
Genetic factors influencing pyrimidine-antagonist chemotherapy.
TL;DR: In this review, proteins relevant for the efficacy and toxicity of pyrimidine antagonists will be summarised, and the role of germline polymorphisms, tumour-specific somatic mutations and protein expression levels in the metabolic pathways and clinical pharmacology of these drugs are described.
124
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
J. Van Meerbeeck,P. Baas,C. Debruyne,H. Groen,Christian Manegold,Andrea Ardizzoni,C. Gridelli,E. Van Marck,Ma. Lentz,G. Giaccone +9 more
TL;DR: At the prescribed dosage and schedule, single agent gemcitabine appears to have limited activity in chemotherapy-naive patients with malignant pleural mesothelioma.
86
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
J. Van Meerbeeck,C. Debruyne,N. van Zandwijk,Pe Postmus,M.C. Pennucci,F.J.M. van Breukelen,D. Galdermans,H. Groen,P. Pinson,M. van Glabbeke,E. Van Marck,G. Giaccone +11 more
TL;DR: In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.
82
Caelyx™ in malignant mesothelioma: A phase II EORTC study
TL;DR: At the prescribed dose, single agent Caelyx is well tolerated but its activity in chemotherapy-naive mesothelioma patients does not warrant further investigation as a single agent.
53